Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Drug therapy for osteoporosis is widely accepted. Bisphosphonates in particular significantly inhibit bone resorption by suppressing osteoclast activity and increasing bone density [1–3]. Alendronate is one of these bisphosphonates; it was approved in the United States in the 1990s and is commonly prescribed worldwide [1, 4, 5]. Clinical trials have shown its effectiveness in the treatment of fractures related to postmenopausal osteoporosis . However, some recent reports have described unusual subtrochanteric or femoral shaft fractures following long-term alendronate therapy [4, 7–13]. Although no causal relationship between long-term alendronate treatment and these atypical stress fractures has been established, some reports suggest that the severe suppression of bone turnover by alendronate may lead to accumulated microdamage to the bone that subsequently results in complete fracture [4, 12].
In this report, we describe a patient who experienced prodromal pain and 14 mo ...
- Bone, HG, Hosking, D, Devogelaer, JP, Tucci, JR, Emkey, RD, Tonino, RP, Rodriguez-Portales, JA, Downs, RW, Gupta, J, Santora, AC, Liberman, UA (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: pp. 1189-1199 CrossRef
- Drake, MT, Clarke, BL, Khosla, S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: pp. 1032-1045 CrossRef
- Watts, NB, Diab, DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95: pp. 1555-1565 CrossRef
- Sayed-Noor, AS, Sjödén, GO (2009) Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 467: pp. 1921-1926 CrossRef
- Shane, E (2010) Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362: pp. 1825-1827 CrossRef
- Bilezikian, JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122: pp. S14-S21 CrossRef
- Cermak, K, Shumelinsky, F, Alexiou, J, Gebhart, MJ (2010) Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 468: pp. 1991-1996 CrossRef
- Goh, SK, Yang, KY, Koh, JS, Wong, MK, Chua, SY, Chua, DT, Howe, TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89: pp. 349-353 CrossRef
- Kwek, EB, Goh, SK, Koh, JS, Png, MA, Howe, TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 39: pp. 224-231 CrossRef
- Lenart, BA, Lorich, DG, Lane, JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358: pp. 1304-1306 CrossRef
- Odvina, CV, Zerwekh, JE, Rao, DS, Maalouf, N, Gottschalk, FA, Pak, CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: pp. 1294-1301 CrossRef
- Odvina, CV, Levy, S, Rao, S, Zerwekh, JE, Rao, DS (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 72: pp. 161-168 CrossRef
- Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-term alendronate use not without consequences? Int J Rheumatol. 2009.
- Kanis, JA, Melton, LJ, Christiansen, C, Johnston, CC, Khaltaev, N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9: pp. 1137-1141 CrossRef
- Kwek, EB, Koh, JS, Howe, TS (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359: pp. 316-317 CrossRef
- Japanese Guidelines for the Prevention and Treatment of Osteoporosis 2006 edition. Life Science Publishing, Tokyo, 2006:73–102 (in Japanese).
- Shane, E, Burr, D, Ebeling, PR, Abrahamsen, B, Adler, RA, Brown, TD, Cheung, AM, Cosman, F, Curtis, JR, Dell, R, Dempster, D, Einhorn, TA, Genant, HK, Geusens, P, Klaushofer, K, Koval, K, Lane, JM, McKiernan, F, McKinney, R, Ng, A, Nieves, J, O’Keefe, R, Papapoulos, S, Sen, HT, Meulen, MC, Weinstein, RS, Whyte, M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: pp. 2267-2294 CrossRef
- Das De, S, Setiobudi, T, Shen, L, Das De, S (2010) A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 92: pp. 679-686 CrossRef
- Somford, MP, Draijer, FW, Thomassen, BJ, Chavassieux, PM, Boivin, G, Papapoulos, SE (2009) Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 24: pp. 1736-1740 CrossRef
- Lee, P, Seibel, MJ (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359: pp. 317
- Sims, SH (2002) Subtrochanteric femur fractures. Orthop Clin North Am 33: pp. 113-126 CrossRef
- Online version of Gray’s anatomy. Available at http://www.bartleby.com/107/59.html. Accessed Oct 20, 2010.
- Mashiba, T, Hirano, T, Turner, CH, Forwood, MR, Johnston, CC, Burr, DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: pp. 613-620 CrossRef
- Medicines and Healthcare Products Regulatory Agency (MHRA). Bisphosphonate: atypical stress fractures. Drug safety update 2 (8). Available at http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON041211. Accessed Oct 13, 2010.
- Lin, JH, Duggan, DE, Chen, IW, Ellsworth, RL (1991) Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19: pp. 926-932
- Black, DM, Schwartz, AV, Ensrud, KE, Cauley, JA, Levis, S, Quandt, SA, Satterfield, S, Wallace, RB, Bauer, DC, Palermo, L, Wehren, , Lombardi, A, Santora, AC, Cummings, SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: pp. 2927-2938 CrossRef
- Noth, I, Strek, ME, Leff, AR (2003) Churg–Strauss syndrome. Lancet 361: pp. 587-594 CrossRef
- Abrahamsen, B, Eiken, P, Eastell, R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24: pp. 1095-1102 CrossRef
- Black, DM, Kelly, MP, Genant, HK, Palermo, L, Eastell, R, Bucci-Rechtweg, C, Cauley, J, Leung, PC, Boonen, S, Santora, A, Papp, A, Bauer, DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362: pp. 1761-1771 CrossRef
- Dobnig, H, Stepan, JJ, Burr, DB, Li, J, Michalská, D, Sipos, A, Petto, H, Fahrleitner-Pammer, A, Pavo, I (2009) Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 24: pp. 1998-2006 CrossRef
- Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy
Journal of Orthopaedic Science
Volume 17, Issue 3 , pp 313-318
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Industry Sectors